Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6893)
All Articles published online
|
Feb 7, 2013 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn’s disease. World J Gastroenterol 2013; 19(5): 648-653 [PMID: 23429474 DOI: 10.3748/wjg.v19.i5.648] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i5/648.htm |
| Number | Citing Articles |
| 1 |
Saeed Shakibfar, Kristine Allin, Tine Jess, Maria Antonietta Barbieri, Vera Battini, Eva Simoncic, Julien Kirchgesner, Trond Ulven, Maurizio Sessa. Drug Repurposing in Crohn’s Disease Using Danish Real-World Data. Pragmatic and Observational Research 2024; : 17 doi: 10.2147/POR.S444569
|
| 2 |
|
| 3 |
Emma Slack, Maria L. Balmer, Andrew J. Macpherson. B cells as a critical node in the microbiota–host immune system network . Immunological Reviews 2014; 260(1): 50 doi: 10.1111/imr.12179
|
| 4 |
Franz Hartmann. Durchfälle und Bauchschmerzen – was steckt dahinter?. MMW - Fortschritte der Medizin 2013; 155(25): 57 doi: 10.1007/s15006-013-2128-x
|
| 5 |
Herbert L. DuPont. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clinic Proceedings 2015; 90(8): 1116 doi: 10.1016/j.mayocp.2015.04.016
|
| 6 |
R. B. Sartor. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 2016; 43(S1): 27 doi: 10.1111/apt.13436
|
| 7 |
Morris Gordon, Vassiliki Sinopoulou, Ciaran Grafton-Clarke, Anthony K Akobeng. Antibiotics for the induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2022; 2022(5) doi: 10.1002/14651858.CD013743.pub2
|
| 8 |
Neil D. Goldberg, Aravinda Vadlamudi, Nicole Parrish. Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole. Case Reports in Gastroenterology 2015; 9(1): 25 doi: 10.1159/000369965
|
| 9 |
Anna Wajda, Larysa Sivitskaya, Agnieszka Paradowska-Gorycka. Application of NGS Technology in Understanding the Pathology of Autoimmune Diseases. Journal of Clinical Medicine 2021; 10(15): 3334 doi: 10.3390/jcm10153334
|
| 10 |
Cassandra M Townsend, Claire E Parker, John K MacDonald, Tran M Nguyen, Vipul Jairath, Brian G Feagan, Reena Khanna. Antibiotics for induction and maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2019; doi: 10.1002/14651858.CD012730.pub2
|
| 11 |
Morris Gordon, Ciaran Grafton-Clarke, Vassiliki Sinopoulou, Anthony K Akobeng. Antibiotics for the induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2020; doi: 10.1002/14651858.CD013743
|
| 12 |
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen, A Barney Hawthorne. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68(Suppl 3): s1 doi: 10.1136/gutjnl-2019-318484
|
| 13 |
Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti, Antonio Gasbarrini. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018; 27(6): 543 doi: 10.1080/13543784.2018.1483333
|
| 14 |
Daya K. Jha, Shubhra Mishra, Usha Dutta, Vishal Sharma. Antibiotics for inflammatory bowel disease: Current status. Indian Journal of Gastroenterology 2024; 43(1): 145 doi: 10.1007/s12664-024-01537-x
|
| 15 |
Aditi Kumar, Hafid O. Al-Hassi, Helen Steed, Oliver Phipps, Matthew J. Brookes, Masanao Nakamura. Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology 2022; 2022: 1 doi: 10.1155/2022/8416578
|
| 16 |
Scott A. Strong. The ASCRS Textbook of Colon and Rectal Surgery. 2016; : 807 doi: 10.1007/978-3-319-25970-3_47
|
| 17 |
Shuo Yuan, Ke-Si Wang, Huan Meng, Xiao-Ting Hou, Jia-Chen Xue, Bao-Hong Liu, Wen-Wen Cheng, Jiao Li, Hua-Min Zhang, Ji-Xing Nan, Qing-Gao Zhang. The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy. Biomedicine & Pharmacotherapy 2023; 165: 114893 doi: 10.1016/j.biopha.2023.114893
|
| 18 |
Adeline Sivignon, Julie Bouckaert, Julien Bernard, Sebastien G. Gouin, Nicolas Barnich. The potential of FimH as a novel therapeutic target for the treatment of Crohn’s disease. Expert Opinion on Therapeutic Targets 2017; 21(9): 837 doi: 10.1080/14728222.2017.1363184
|
| 19 |
Maria Lia Scribano, Cosimo Prantera. Antibiotics and Inflammatory Bowel Diseases. Digestive Diseases 2013; 31(3-4): 379 doi: 10.1159/000354704
|
| 20 |
Daniel Sprockett, Natalie Fischer, Rotem Sigall Boneh, Dan Turner, Jarek Kierkus, Malgorzata Sladek, Johanna C Escher, Eytan Wine, Baruch Yerushalmi, Jorge Amil Dias, Ron Shaoul, Michal Kori, Scott B Snapper, Susan Holmes, Athos Bousvaros, Arie Levine, David A Relman. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn’s Disease Cohort. Inflammatory Bowel Diseases 2019; 25(12): 1927 doi: 10.1093/ibd/izz130
|
| 21 |
Sushila R. Dalal, Eugene B. Chang. The microbial basis of inflammatory bowel diseases. Journal of Clinical Investigation 2014; 124(10): 4190 doi: 10.1172/JCI72330
|
| 22 |
Peter Girgis, Tanisha LNU, Amna Ahmad, Mina Daniel, Maria Kamel, Jade L Gambill, Atika Shahzadi, Usman Khan, Anam Zara, Vagisha Sharma. Advancements in Targeted Therapies for the Management of Crohn’s Disease: A Comprehensive Review. Cureus 2024; doi: 10.7759/cureus.61751
|
| 23 |
Allison Agus, Sébastien Massier, Arlette Darfeuille-Michaud, Elisabeth Billard, Nicolas Barnich. Understanding Host-Adherent-InvasiveEscherichia coliInteraction in Crohn’s Disease: Opening Up New Therapeutic Strategies. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/567929
|
| 24 |
Cristina Rosário, Rita Noversa de Sousa. Infection and Autoimmunity. 2024; : 407 doi: 10.1016/B978-0-323-99130-8.00006-4
|
| 25 |
Mario Matijašić, Tomislav Meštrović, Mihaela Perić, Hana Čipčić Paljetak, Marina Panek, Darija Vranešić Bender, Dina Ljubas Kelečić, Željko Krznarić, Donatella Verbanac. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. International Journal of Molecular Sciences 2016; 17(4): 578 doi: 10.3390/ijms17040578
|
| 26 |
Cassandra M Townsend, Claire E Parker, John K MacDonald, Vipul Jairath, Brian G Feagan, Reena Khanna. Antibiotics for induction and maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017; doi: 10.1002/14651858.CD012730
|